Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? - PubMed
- ️Thu Jan 01 2004
Comparative Study
. 2004 Nov 15;101(10):2214-21.
doi: 10.1002/cncr.20645.
Affiliations
- PMID: 15452833
- DOI: 10.1002/cncr.20645
Free article
Comparative Study
Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
David M Boruta 2nd et al. Cancer. 2004.
Free article
Abstract
Background: Serous components within endometrial carcinoma are reportedly poor prognosticators. However, to the authors' knowledge the percentage of tumors which must be comprised of a serous component in order to affect outcome is unknown. The authors compared overall survival (OS) in women with endometrial carcinomas comprised of various percentages of uterine serous carcinoma (USC) with that of women with International Federation of Gynecology and Obstetrics (FIGO) Grade 3 endometrioid carcinoma (G3EC) to determine whether outcomes varied between these two poorly differentiated histologies.
Methods: Data concerning women with either G3EC or USC who were diagnosed between January 1990 and November 2000 were collected retrospectively. Cases were reviewed to confirm diagnosis and estimate the fraction of tumor comprised of USC. Variables assessed included patient age and race, tumor stage, and lymphovascular space invasion. Associations between variables were tested using the Fisher exact test. The Kaplan-Meier method was used to evaluate OS with comparisons performed using the log-rank test.
Results: Fifty-two women with G3EC and 87 women with USC were identified. The OS of women with tumors comprised of > 50% USC was found to be significantly worse compared with women with G3EC (hazard ratio [HR] of 2.4; 95% confidence interval [95% CI], 1.2-5.2). Women with USC were more likely to present with extrauterine disease (odds ratio of 2.2; 95% CI, 1.1-4.5). The 5-year survival rate for women with G3EC was 75% compared with 41% for women with tumors that were > 50% USC (P = 0.01). There was a significant trend toward a worse OS in women with even 10% USC compared with women with G3EC.
Conclusions: USC involving > 50% of an endometrial carcinoma was found to be predictive of worse OS compared with the OS of women with G3EC. In patients with early-stage disease, a trend toward a worse prognosis was found to exist when USC comprised even 10% of a tumor. Investigation into the treatment of endometrial carcinoma should include and document tumors with any percentage comprised of USC.
(c) 2004 American Cancer Society
Comment in
-
The controversies surrounding the management of uterine serous carcinoma.
Munkarah AR. Munkarah AR. Cancer. 2004 Nov 15;101(10):2152-4. doi: 10.1002/cncr.20651. Cancer. 2004. PMID: 15389471 Review. No abstract available.
Similar articles
-
Park JY, Nam JH, Kim YT, Kim YM, Kim JH, Kim DY, Sohn I, Lee SW, Sung CO, Kim KR. Park JY, et al. Virchows Arch. 2013 Mar;462(3):289-96. doi: 10.1007/s00428-013-1382-8. Epub 2013 Feb 17. Virchows Arch. 2013. PMID: 23417747
-
Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, Keeney GL, Long HJ 3rd, Dowdy SC, Podratz KC. Ayeni TA, et al. Gynecol Oncol. 2013 Jun;129(3):478-85. doi: 10.1016/j.ygyno.2013.03.011. Epub 2013 Mar 25. Gynecol Oncol. 2013. PMID: 23535279
-
Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD. Bansal N, et al. Obstet Gynecol. 2008 Jul;112(1):64-70. doi: 10.1097/AOG.0b013e318176157c. Obstet Gynecol. 2008. PMID: 18591309
-
Molecular alterations in uterine serous carcinoma.
Hayes MP, Ellenson LH. Hayes MP, et al. Gynecol Oncol. 2010 Feb;116(2):286-9. doi: 10.1016/j.ygyno.2009.11.012. Gynecol Oncol. 2010. PMID: 20109727 Review.
-
Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis.
Rabban JT, Zaloudek CJ. Rabban JT, et al. Pathology. 2007 Feb;39(1):125-33. doi: 10.1080/00313020601146814. Pathology. 2007. PMID: 17365828 Review.
Cited by
-
Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.
Ebring C, Marlin R, Macni J, Vallard A, Bergerac S, Beaubrun-Renard M, Joachim C, Jean-Laurent M. Ebring C, et al. PLoS One. 2023 Mar 16;18(3):e0278757. doi: 10.1371/journal.pone.0278757. eCollection 2023. PLoS One. 2023. PMID: 36928660 Free PMC article.
-
Nakayama K, Nakayama N, Ishikawa M, Miyazaki K. Nakayama K, et al. Cancers (Basel). 2012 Aug 7;4(3):799-807. doi: 10.3390/cancers4030799. Cancers (Basel). 2012. PMID: 24213467 Free PMC article.
-
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King MC, Goodfellow P, Swisher EM. Pennington KP, et al. Cancer. 2013 Jan 15;119(2):332-8. doi: 10.1002/cncr.27720. Epub 2012 Jul 18. Cancer. 2013. PMID: 22811390 Free PMC article.
-
The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches.
Bruchim I, Sarfstein R, Werner H. Bruchim I, et al. Front Endocrinol (Lausanne). 2014 May 19;5:76. doi: 10.3389/fendo.2014.00076. eCollection 2014. Front Endocrinol (Lausanne). 2014. PMID: 24904527 Free PMC article. Review.
-
Casey MJ, Colanta AB. Casey MJ, et al. Fam Cancer. 2016 Jul;15(3):371-84. doi: 10.1007/s10689-016-9878-4. Fam Cancer. 2016. PMID: 26875157 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical